Carotid artery intima-media thickness in patients with autoimmune connective tissue diseases: a case-control study

Vincenzo Bruzzese1, Cinzia Marrese, Angelo Zullo

  • 1Internal Medicine and Reumatology, Ospedale Nuovo Regina Margherita, Vie E. Morosini, 30, 00153, Rome, Italy, vinbruzzese@tin.it.

Insights

Cardiovascular risk in autoimmune rheumatic disorders is linked to traditional factors like age, not systemic inflammation. Preclinical atherosclerosis was similar in patients and controls, highlighting the importance of managing common risk factors.

Area of Science:

  • Rheumatology
  • Cardiovascular Medicine
  • Immunology

Background:

  • Patients with autoimmune rheumatic disorders exhibit higher cardiovascular (CV) event rates and mortality.
  • While traditional CV risk factors are prevalent, systemic inflammation is debated as an independent CV risk factor, especially in rheumatoid arthritis (RA).

Purpose of the Study:

  • To investigate the prevalence of preclinical atherosclerosis in patients with autoimmune rheumatic disorders compared to matched controls.
  • To identify independent predictors of early atherosclerosis in this patient population.

Main Methods:

  • A case-control study involving 152 patients with autoimmune rheumatic disorders and 140 matched controls.
  • Assessment of early atherosclerosis using carotid artery intima-media thickness (IMT) measurement (normal ≤ 0.9 mm, abnormal > 0.9 mm).
  • Multivariate analysis to determine predictors of pathological IMT.

Main Results:

  • No significant difference in the prevalence of abnormal IMT (>0.9 mm) between patients (61%) and controls (69%).
  • Similar IMT distribution observed between rheumatoid arthritis patients and controls.
  • Presence of CV risk factors significantly increased the prevalence of pathological IMT in both patients (77.1%) and controls (84.6%).
  • Age and traditional CV risk factors, not rheumatic disease, were identified as independent predictors of pathological IMT.

Conclusions:

  • Autoimmune rheumatic diseases, including RA, do not show a higher prevalence of preclinical arterial wall atherosclerotic damage compared to matched controls.
  • Traditional CV risk factors and patient age are the primary determinants of preclinical atherosclerosis in patients with autoimmune rheumatic disorders.

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...